+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Genome Editing / Genome Engineering: Global Strategic Business Report

  • PDF Icon

    Report

  • 187 Pages
  • October 2022
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 4805049

Global Genome Editing / Genome Engineering Market to Reach $19.3 Billion by 2027

In the changed post COVID-19 business landscape, the global market for Genome Editing / Genome Engineering estimated at US$5.4 Billion in the year 2020, is projected to reach a revised size of US$19.3 Billion by 2027, growing at a CAGR of 19.9% over the analysis period 2020-2027. CRISPR, one of the segments analyzed in the report, is projected to record a 22.6% CAGR and reach US$9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the ZFN segment is readjusted to a revised 15.2% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.6 Billion, While China is Forecast to Grow at 19.3% CAGR

The Genome Editing / Genome Engineering market in the U.S. is estimated at US$1.6 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$3.3 Billion by the year 2027 trailing a CAGR of 19.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.6% and 16.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 13.7% CAGR.

TALEN Segment to Record 20.6% CAGR

In the global TALEN segment, USA, Canada, Japan, China and Europe will drive the 20.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$916.7 Million in the year 2020 will reach a projected size of US$3.4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

Select Competitors (Total 27 Featured) -

  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • GenScript Biotech Corporation
  • Horizon Discovery Group PLC
  • Integrated DNA Technologies (IDT), Inc.
  • Lonza Group AG
  • Merck & Co., Inc.
  • New England Biolabs, Inc.
  • OriGene Technologies, Inc.
  • Sangamo Therapeutics
  • Thermo Fisher Scientific, Inc.
  • Transposagen Biopharmaceuticals, Inc.

What's New for 2022?

  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and a Research Platform
  • Complimentary updates for one year
Frequently Asked Questions about the Global Market for Genome Editing / Genome Engineering

What is the estimated value of the Global Market for Genome Editing / Genome Engineering?

The Global Market for Genome Editing / Genome Engineering was estimated to be valued at $5.4 Billion in 2020.

What is the growth rate of the Global Market for Genome Editing / Genome Engineering?

The growth rate of the Global Market for Genome Editing / Genome Engineering is 20.0%, with an estimated value of $19.3 Billion by 2027.

What is the forecasted size of the Global Market for Genome Editing / Genome Engineering?

The Global Market for Genome Editing / Genome Engineering is estimated to be worth $19.3 Billion by 2027.

Who are the key companies in the Global Market for Genome Editing / Genome Engineering?

Key companies in the Global Market for Genome Editing / Genome Engineering include CRISPR Therapeutics AG, Editas Medicine, Inc., GenScript Biotech Corporation, Horizon Discovery Group PLC, Integrated DNA Technologies (IDT), Inc., Lonza Group AG, Merck & Co., Inc., New England Biolabs, Inc. and Sangamo Therapeutics.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Genome Editing/Genome Engineering - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 2: World 7-Year Perspective for Genome Editing / Genome Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2021 & 2027
  • Table 3: World Recent Past, Current & Future Analysis for CRISPR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 4: World 7-Year Perspective for CRISPR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
  • Table 5: World Recent Past, Current & Future Analysis for TALEN by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 6: World 7-Year Perspective for TALEN by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
  • Table 7: World Recent Past, Current & Future Analysis for ZFN by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 8: World 7-Year Perspective for ZFN by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
  • Table 9: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 10: World 7-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
  • Table 11: World Genome Editing / Genome Engineering Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027
  • Table 12: World Recent Past, Current & Future Analysis for Ex-Vivo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 13: World 7-Year Perspective for Ex-Vivo by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
  • Table 14: World Recent Past, Current & Future Analysis for In-Vivo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 15: World 7-Year Perspective for In-Vivo by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
  • Table 16: World Recent Past, Current & Future Analysis for Genetic Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 17: World 7-Year Perspective for Genetic Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
  • Table 18: World Recent Past, Current & Future Analysis for Clinical Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 19: World 7-Year Perspective for Clinical Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
  • Table 20: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 21: World 7-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
  • Table 22: World Recent Past, Current & Future Analysis for Academic & Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 23: World 7-Year Perspective for Academic & Government Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
  • Table 24: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 25: World 7-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
III. MARKET ANALYSIS
UNITED STATES
  • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
  • Table 26: USA Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 27: USA 7-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2021 & 2027
  • Table 28: USA Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 29: USA 7-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2021 & 2027
  • Table 30: USA Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 31: USA 7-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2021 & 2027
  • Table 32: USA Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 33: USA 7-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2021 & 2027
CANADA
  • Table 34: Canada Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 35: Canada 7-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2021 & 2027
  • Table 36: Canada Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 37: Canada 7-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2021 & 2027
  • Table 38: Canada Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 39: Canada 7-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2021 & 2027
  • Table 40: Canada Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 41: Canada 7-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2021 & 2027
JAPAN
  • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
  • Table 42: Japan Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 43: Japan 7-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2021 & 2027
  • Table 44: Japan Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 45: Japan 7-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2021 & 2027
  • Table 46: Japan Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 47: Japan 7-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2021 & 2027
  • Table 48: Japan Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 49: Japan 7-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2021 & 2027
CHINA
  • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
  • Table 50: China Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 51: China 7-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2021 & 2027
  • Table 52: China Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 53: China 7-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2021 & 2027
  • Table 54: China Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 55: China 7-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2021 & 2027
  • Table 56: China Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 57: China 7-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2021 & 2027
EUROPE
  • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
  • Table 58: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 59: Europe 7-Year Perspective for Genome Editing / Genome Engineering by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2021 & 2027
  • Table 60: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 61: Europe 7-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2021 & 2027
  • Table 62: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 63: Europe 7-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2021 & 2027
  • Table 64: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 65: Europe 7-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2021 & 2027
  • Table 66: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 67: Europe 7-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2021 & 2027
FRANCE
  • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
  • Table 68: France Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 69: France 7-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2021 & 2027
  • Table 70: France Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 71: France 7-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2021 & 2027
  • Table 72: France Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 73: France 7-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2021 & 2027
  • Table 74: France Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 75: France 7-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2021 & 2027
GERMANY
  • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
  • Table 76: Germany Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 77: Germany 7-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2021 & 2027
  • Table 78: Germany Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 79: Germany 7-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2021 & 2027
  • Table 80: Germany Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 81: Germany 7-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2021 & 2027
  • Table 82: Germany Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 83: Germany 7-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2021 & 2027
ITALY
  • Table 84: Italy Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 85: Italy 7-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2021 & 2027
  • Table 86: Italy Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 87: Italy 7-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2021 & 2027
  • Table 88: Italy Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 89: Italy 7-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2021 & 2027
  • Table 90: Italy Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 91: Italy 7-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2021 & 2027
UNITED KINGDOM
  • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
  • Table 92: UK Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 93: UK 7-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2021 & 2027
  • Table 94: UK Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 95: UK 7-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2021 & 2027
  • Table 96: UK Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 97: UK 7-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2021 & 2027
  • Table 98: UK Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 99: UK 7-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2021 & 2027
REST OF EUROPE
  • Table 100: Rest of Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 101: Rest of Europe 7-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2021 & 2027
  • Table 102: Rest of Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 103: Rest of Europe 7-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2021 & 2027
  • Table 104: Rest of Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 105: Rest of Europe 7-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2021 & 2027
  • Table 106: Rest of Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 107: Rest of Europe 7-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2021 & 2027
ASIA-PACIFIC
  • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
  • Table 108: Asia-Pacific Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 109: Asia-Pacific 7-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2021 & 2027
  • Table 110: Asia-Pacific Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 111: Asia-Pacific 7-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2021 & 2027
  • Table 112: Asia-Pacific Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 113: Asia-Pacific 7-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2021 & 2027
  • Table 114: Asia-Pacific Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 115: Asia-Pacific 7-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2021 & 2027
REST OF WORLD
  • Table 116: Rest of World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 117: Rest of World 7-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2021 & 2027
  • Table 118: Rest of World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 119: Rest of World 7-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2021 & 2027
  • Table 120: Rest of World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 121: Rest of World 7-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2021 & 2027
  • Table 122: Rest of World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 123: Rest of World 7-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2021 & 2027
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • GenScript Biotech Corporation
  • Horizon Discovery Group PLC
  • Integrated DNA Technologies (IDT), Inc.
  • Lonza Group AG
  • Merck & Co., Inc.
  • New England Biolabs, Inc.
  • OriGene Technologies, Inc.
  • Sangamo Therapeutics
  • Thermo Fisher Scientific, Inc.
  • Transposagen Biopharmaceuticals, Inc.